Hepatocyte Growth Factor Pipeline and Therapeutics Development H1 2017 provides a comprehensive information on the therapeutics under development for Hepatocyte Growth Factor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Hepatocyte Growth Factor Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Hepatocyte Growth Factor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Hepatocyte Growth Factor pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Sample copy is available at: www.marketinsightsreports.com/repo…w-h2-2017/inquiry
According to the recently published report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing.
In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.
The report 'Hepatocyte Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Hematological Disorders, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Non-Small Cell Lung Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Angina (Angina Pectoris), Arteriosclerosis, Chronic Heart Failure, Colorectal Cancer, Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Myocardial Ischemia, Parkinson's Disease, Rheumatoid Arthritis, Solid Tumor and Thromboangiitis obliterans (Buerger disease).
Browse full Report at: www.marketinsightsreports.com/repo…ne-review-h2-2017
Scope of this report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocyte Growth Factor. The pipeline guide reviews pipeline therapeutics for Hepatocyte Growth Factor by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocyte Growth Factor therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hepatocyte Growth Factor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocyte Growth Factor.
- This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocyte Growth Factor. Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocyte Growth Factor pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Category: Market Research Publishers and RetailersCompany profile: MarketInsightsReports is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resource, automobile, IT, technology and media, food and beverages, and consumer goods, among others.
For more information:Make an Inquiry about this report HERE!